




Q3 2024 Financial Results



Total Revenues
\$3.8B

Adjusted EBITDA*
\$1.3B

Free Cash Flow*
Excluding Transaction Costs
\$866M

Adjusted EPS*
\$0.75




Expects 2024 Full-Year Operational Revenue Growth of ~2%*



"I am very pleased to report strong third quarter results that continue the momentum we've seen all year," said Scott A. Smith, chief executive officer, Viatris. "We are in a period of strong global execution which has led to consistent base business growth and we expect this momentum to continue into next year. Our company is operating from a position of financial strength with a clear and focused outlook that centers on capital allocation. Returning value to shareholders through dividends and share repurchases will remain a central element of optimizing and maximizing shareholder value. We will balance this with making disciplined investments in commercialized or late-stage assets through regional and global business development to drive our future growth."


– Scott A. Smith
Chief Executive Officer

Three Strategic Pillars to Accelerate Growth and Shareholder Return


 <p>DIVERSIFIED & GROWING BASE BUSINESS</p> <p>Sixth consecutive quarter of divestiture-adjusted operational revenue growth with growth across all segments</p> <hr/> <p>Delivered new product revenue of \$133M in Q3 and \$497M YTD</p> <hr/> <p>Positive top-line results of Phase 3 study evaluating safety and efficacy of EFFEXOR® in Japanese adults with generalized anxiety disorder</p>	 <p>FINANCIAL STRENGTH & SIGNIFICANT CASH FLOW</p> <p>Retired ~\$1.9B of debt⁽¹⁾ and expect to achieve long-term gross leverage target of ~3.0x by the end of 2024</p> <hr/> <p>Generated free cash flow of \$866M in Q3 and \$1.9B YTD⁽²⁾</p>	 <p>EXPANDING INNOVATIVE PORTFOLIO</p> <p>Entered into exclusive licensing agreement for sotagliflozin in October 2024, expanding our innovative portfolio in cardiovascular diseases</p>
---	--	---

Building Sustainable Access at Scale

 Supplying high-quality medicines to ~1 billion patients around the world annually⁽³⁾



Viatris named to **Forbes' World's Best Employers 2024 List** for the fourth year in a row. Recipients were selected from over 300,000 participants across 50 different countries.



Viatris named to **Forbes' World's Top Companies for Women 2024 List**. Honorees were chosen among multi-national corporations and independent surveys of ~100,000 women in 37 countries.

* Non-GAAP Financial Measure. For more information about Non-GAAP financial measures and reconciliations to the closest U.S. GAAP financial measure, as well as risks related to forward-looking statements, please read our [Q3 2024 financial results press release](#) on our website.

⁽¹⁾ Includes the impact of make-whole call of €292M (~\$325M) of remaining 2025 Euro Senior Notes on October 16, 2024.
⁽²⁾ Q3 2024 Free Cash Flow was \$750M. Excluding the impact of transaction costs primarily related to the divestitures of \$116M, Q3 2024 Free Cash Flow was \$866M. Q3 2024 YTD Free Cash Flow was \$1.6B. Excluding the impact of transaction costs primarily related to the divestitures of \$306M, Q3 2024 YTD Free Cash Flow was \$1.9B.

⁽³⁾ See our 2023 Sustainability Report page 4 for more information.



Viatri.com | LinkedIn | @ViatriInc | @ViatriInc | YouTube | Listen Well Podcast

© 2024 Viatris Inc. All Rights Reserved. VIATRIS and the Viatris Logo are trademarks of Mylan Inc., a Viatris Company.